Literature DB >> 6219963

Human normal CTL clones: generation and properties.

D Zagury, D Morgan, G Lenoir, M Fouchard, M Feldman.   

Abstract

This study reports the production of clones of human killer T cells grown in the presence of TCGF4 following sensitization in MLC against (1) allogeneic cells, (2) autologous Bebv+ lymphocytes, or (3) autologous lymphoma cells. Sensitization against the tumor cells required the addition of macrophages. The expression of the cytotoxic activity of the cloned T lymphocytes required re-stimulation with the specific stimulator cells. The cytotoxic activity seemed to be MHC-restricted, since (1) cloned allosensitized CTL lysed their corresponding allogeneic targets, but did not lyse autologous Bebv+ cell or K562 cells; (2) cloned CTL sensitized against autologous Bebv+ cells lysed their autologous targets but not allogeneic Bebv+ targets or K562 cells; and (3) cloned CTL sensitized against autologous Burkitt lymphoma cells lysed their corresponding lymphoma targets or autologous Bebv+ targets but did not lyse allogeneic lymphoma cells or Bebv+ cells from the same allogeneic lymphoma cells or Bebv+ cells from the same allogeneic donors. The cloned CTL were homogeneous in expressing the OK T8 molecules and in being negative for T4, T10 or M1. At any given time, 25-45% of the cloned cells manifested lytic activity. The ultrastructural properties and cell surface OK T markers were different from those of cloned human NK cells. Emphasis is focused on the differences between the structural, functional and culture characteristics of CTL clones produced by direct isolation of MLC responder cells forming conjugates with specific target cells and those of clones from transformed T-cell lines or from T hybridomas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6219963     DOI: 10.1002/ijc.2910310406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

Review 1.  Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?

Authors:  B M Vose
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Interleukin 2 therapy in infectious diseases: rationale and prospects.

Authors:  J P Siegel; A H Rook; J Y Djeu; G V Quinnan
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

3.  Interleukin 2 therapy in infectious diseases: rationale and prospects.

Authors:  J P Siegel; A H Rook; J Y Djeu; G V Quinnan
Journal:  Infection       Date:  1985       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.